Subscribe To
: palantir quickly reverses higher toward a 3-month high, best 4-day gain in six months
Shares of Palantir technologies Inc. PLTR quickly reversed an early pullback to power up 4.0% toward a ...
November 4, 2023, 4:29 pm
Atmus filtration technologies inc. (atmu) q3 2023 earnings call transcript
Atmus Filtration technologies Inc. (ATMU) Q3 2023 Earnings Call Transcript...
November 4, 2023, 12:02 pm
Cps technologies corporation (cpsh) q3 2023 earnings call transcript
CPS technologies Corporation (NASDAQ:CPSH ) Q3 2023 Results Conference Call November 2, 2023 9:00 AM ET...
November 4, 2023, 11:59 am
Faro technologies, inc. (faro) q3 2023 earnings call transcript
FARO technologies, Inc. (NASDAQ:FARO ) Q3 2023 Results Conference Call November 2, 2023 8:00 AM ET Comp...
November 4, 2023, 11:50 am
Here's why cognex stock crashed in october
Consumer electronics, logistics, and automotive spending plans have been held back in 2023. The company's tech...
November 4, 2023, 10:58 am
Nie: discounted but not a bargain
The Virtus Equity & Convertible Income Fund is benefiting from its heavy exposure to mega-cap tech stoc...
November 4, 2023, 9:45 am
Biden's ai executive order: it's about understanding this technology, the risks, says c3.ai ceo
President Biden signed into action a sweeping executive order to promote innovation in artificial intelligence while also seeking to enforce effective...
November 4, 2023, 9:00 am
Palantir q3 earnings: focus on government contracts (rating upgrade)
Palantir technologies reported strong Q3 2023 earnings, indicating significant upside potential for inv...
November 4, 2023, 7:28 am
Buy hershey amid financial and technical strength
The Hershey Company reported strong Q3 2023 financial results, with a substantial increase in net sales driven by organic sales growth and strategic p...
November 4, 2023, 6:23 am
Sedg investor alert: robbins geller rudman & dowd llp announces that solaredge technologies, inc. investors with substantial losses have opportunity to lead the solaredge class action lawsuit
SAN DIEGO, Nov. 03, 2023 (GLOBE NEWSWIRE) — Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of SolarEdge ...
November 4, 2023, 2:55 am
Jack dorsey’s block surges to $2.42 billion in bitcoin revenue
Former Twitter CEO Jack Dorsey’s fintech company Block posted $5.62 billion in total net revenue for ...
November 4, 2023, 2:29 am
Investors sue solaredge technologies (sedg) for stocking up channels with excess inventory– hagens berman
Firm Encourages Investors with Losses to Contact its Attorneys SAN FRANCISCO, Nov. 03, 2023 (GLOBE NEWSWIRE) — Hagens Berman urges SolarEdge ...
November 4, 2023, 2:17 am
Micron is positioned to enjoy the semiconductors next cycle
Micron is an attractive investment opportunity in the information technology sector, operating in the g...
November 4, 2023, 1:39 am
10x genomics: unveiling the investment potential
10x Genomics is a life science technology company with a clear mission and visionary leadership. 10x Ge...
November 4, 2023, 1:02 am
The finance and tech gold rushes are over. where will people seeking wealth turn next?
The tech industry’s gold rush is coming to an end as venture capital funding and IPOs decline. The in...
November 4, 2023, 12:44 am
U.s. ipo weekly recap: biotech lexeo stumbles after $100 million ipo
Two IPOs are currently scheduled for the week ahead, although some small issuers may join the calendar late. As of 11/2/2023, the Renaissance IPO Inde...
November 4, 2023, 12:21 am
Replimune presents updated interim results from the artacus clinical trial of rp1 monotherapy in solid organ and hematopoietic cell transplant recipients with skin cancers during oral presentation at
RP1 as monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent in evaluable patients WOBURN, Mass., Nov. 03, 2...
November 3, 2023, 11:30 pm
Replimune presents updated interim results from the artacus clinical trial of rp1 monotherapy in solid organ and hematopoietic cell transplant recipients with skin cancers during oral presentation at
RP1 as monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent in evaluable patients WOBURN, Mass., Nov. 03, 2...
November 3, 2023, 11:30 pm
Replimune presents updated interim results from the artacus clinical trial of rp1 monotherapy in solid organ and hematopoietic cell transplant recipients with skin cancers during oral presentation at
RP1 as monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent in evaluable patients WOBURN, Mass., Nov. 03, 2...
November 3, 2023, 11:30 pm
Replimune presents updated interim results from the artacus clinical trial of rp1 monotherapy in solid organ and hematopoietic cell transplant recipients with skin cancers during oral presentation at
RP1 as monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent in evaluable patients WOBURN, Mass., Nov. 03, 2...
November 3, 2023, 11:30 pm